Mondobiotech Holding AG Company presentation

More documents

Recommendations

Info

Diversifying the Risk in Drug Discovery • Through our technology the risk is diversified by building up a much larger pipeline to be licensed out to partners • Our model allows drug discovery and development at very limited costs • Our extended pipeline comprises 82 drugs for rare diseases of which: • 9 medicinal candidates ready for licensing • 73 new medicinal candidates in development 40
Licensing Box Information on Products Ready for Licensing is provided to our Partners in a Box containing full scientific, medical, IP and market documentation Box includes: Product Candidate Development Disease Financial Information IP & Legal Offered Services Dossier, API information, Published information In vitro activities, Pre-clinical activities, Clinical activities Disease dossier, Centers of excellence, Patients associations & other key entities, Published data, Development plan Key competitor, Other market information, Projected sales Protection documentation, PCT application, ISR (if available), National applications (if available): USA, Europe, Australia, Canada, Japan, Singapore, United Arab Emirates, Korea, Russia. Orphan drug designations/Orphan drug application and granting (EU/US), EU Regulations, US Regulations, Standard licensing contract and conditions, Standard service contract CRO Services for Clinical Trials Phases I to IV, API, Protocol assistance, Orphan drug & Regulatory assistance, Networking with <strong>Mondobiotech</strong> Community (Scientific, Medical, Centers of excellence, Laboratory, Research organizations and other experts), Scientific & Medical Workshops for developing and prompting the project, Co-marketing, other development services upon request 41
Page 1 and 2: Mondobiotech Holding AG Company pre
Page 3 and 4: mondoBIOTECH at a glance • Headqu
Page 5 and 6: Board of Directors Robert Edward Pa
Page 7 and 8: Our approach to drug discovery •
Page 9 and 10: Introduction to the Search&Match me
Page 11 and 12: The Model • Knowledge from litera
Page 13 and 14: The Search and Match Software Platf
Page 15 and 16: Match • Any path through the know
Page 17 and 18: Match - a multi-technique approach
Page 19 and 20: Bio-Mathematical Technology Platfor
Page 21 and 22: Match - Project DK-0112-01 21
Page 23 and 24: Match - Project DK-1001-01 23
Page 25 and 26: MPC Validation: the mondoBIOTECH Co
Page 27 and 28: Set up of new projects PROJECT SET
Page 29 and 30: Intellectual Property Strategy & Cu
Page 31 and 32: mondoBIOTECH’s IP Strategy Two in
Page 33 and 34: mondoBIOTECH’s IP Strategy: Two I
Page 35 and 36: Orphan Drug Designations 10 Granted
Page 37 and 38: Why Peptides Peptides characteristi
Page 42 and 43: Current Pipeline DasKloster 1000-01
Page 46: Scientific Snapshot Information: DK
Page 49 and 50: Scientific Snapshot Information: DK
Page 51 and 52: Products licensed DasKloster 1001-0
Page 53 and 54: Licensed Products • Aviptadil pla
Page 55: mondoBIOTECH holding AG DasKloster

Mondobiotech Holding AG Company presentation

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?